CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

This study tests whether dapagliflozin — a medication commonly used for diabetes and heart failure — can protect the heart in breast cancer patients who are receiving anthracycline chemotherapy, which is known to sometimes cause heart damage. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with invasive breast cancer (stage I–III) - You are scheduled to start anthracycline-based chemotherapy within 60 days **You may NOT be eligible if...** - You have a urinary tract infection requiring antibiotics within 48 hours of starting chemotherapy - You have known heart failure or heart failure symptoms - Your heart pumping function (ejection fraction) is below 50% - You have severe heart valve disease, a history of significant irregular heartbeat, or a history of stroke - You have a pre-existing cardiomyopathy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.